Paul Zuck
Overview
Explore the profile of Paul Zuck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu G, Keller S, Walters R, Li Y, Kristoff J, Magliaro B, et al.
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859395
Despite the success of combination antiretroviral therapy (cART) to suppress HIV replication, HIV persists in a long-lived reservoir that can give rise to rebounding viremia upon cART cessation. The translationally...
2.
Wu G, Keller S, Sardo L, Magliaro B, Zuck P, Balibar C, et al.
Biomark Res
. 2024 Oct;
12(1):116.
PMID: 39380117
Background: Latency remains a major obstacle to finding a cure for HIV despite the availability of antiretroviral therapy. Due to virus dormancy, limited biomarkers are available to identify latent HIV-infected...
3.
Wietgrefe S, Anderson J, Duan L, Southern P, Zuck P, Wu G, et al.
J Clin Invest
. 2023 Sep;
133(22).
PMID: 37733443
Productively infected cells are generally thought to arise from HIV infection of activated CD4+ T cells, and these infected activated cells are thought to be a recurring source of latently...
4.
Balibar C, Klein D, Zamlynny B, Diamond T, Fang Z, Cheney C, et al.
Sci Transl Med
. 2023 Feb;
15(684):eabn2038.
PMID: 36812345
Antiretroviral therapy inhibits HIV-1 replication but is not curative due to establishment of a persistent reservoir after virus integration into the host genome. Reservoir reduction is therefore an important HIV-1...
5.
Moore K, Schwaid A, Tudor M, Park S, Beshore D, Converso A, et al.
ACS Chem Biol
. 2022 Aug;
17(9):2595-2604.
PMID: 36044633
Although current antiretroviral therapy can control HIV-1 replication and prevent disease progression, it is not curative. Identifying mechanisms that can lead to eradication of persistent viral reservoirs in people living...
6.
Wietgrefe S, Duan L, Anderson J, Marques G, Sanders M, Cummins N, et al.
J Virol
. 2022 Jul;
96(15):e0088522.
PMID: 35856674
Anti-retroviral therapy (ART) generally suppresses HIV replication to undetectable levels in peripheral blood, but immune activation associated with increased morbidity and mortality is sustained during ART, and infection rebounds when...
7.
Falcinelli S, Peterson J, Turner A, Irlbeck D, Read J, Raines S, et al.
J Clin Invest
. 2022 Apr;
132(8).
PMID: 35426377
Latency reversal strategies for HIV cure using inhibitor of apoptosis protein (IAP) antagonists (IAPi) induce unprecedented levels of latent reservoir expression without immunotoxicity during suppressive antiretroviral therapy (ART). However, full...
8.
Squadroni B, Newhard W, Carr D, Trinh H, Racine F, Zuck P, et al.
SLAS Technol
. 2022 Apr;
27(4):247-252.
PMID: 35367399
Dynamic in vitro antibacterial studies provide valuable insight on effective dosing strategies prior to translating to in vivo models. Frequent sampling is required to monitor the pharmacodynamics (PD) of these...
9.
McMahon J, Evans V, Lau J, Symons J, Zerbato J, Chang J, et al.
AIDS
. 2021 Sep;
36(1):75-82.
PMID: 34586085
Objective: The aim of this study was to examine whether administering both vorinostat and disulfiram to people with HIV (PWH) on antiretroviral therapy (ART) is well tolerated and can enhance...
10.
Wu G, Cheney C, Huang Q, Hazuda D, Howell B, Zuck P
Front Microbiol
. 2021 Apr;
12:636703.
PMID: 33796087
Greater than 90% of HIV-1 proviruses are thought to be defective and incapable of viral replication. While replication competent proviruses are of primary concern with respect to disease progression or...